Pulmatrix, Inc.PULMEarnings & Financial Report
Pulmatrix, Inc. is a clinical-stage biopharmaceutical firm specializing in developing innovative inhaled therapies for severe respiratory diseases including chronic obstructive pulmonary disease, cystic fibrosis and idiopathic pulmonary fibrosis. It uses its proprietary dry powder platform to improve inhaled medication efficacy and safety, advancing its product candidate pipeline via partnerships with global pharmaceutical players.
PULM Q2 FY2024 Key Financial Metrics
Revenue
$1.6M
Gross Profit
N/A
Operating Profit
$-5.9M
Net Profit
$-5.8M
Gross Margin
N/A
Operating Margin
-380.2%
Net Margin
-374.4%
YoY Growth
-15.8%
EPS
$-1.59
Pulmatrix, Inc. Q2 FY2024 Financial Summary
Pulmatrix, Inc. reported revenue of $1.6M (down 15.8% YoY) for Q2 FY2024, with a net profit of $-5.8M (down 52.3% YoY) (-374.4% margin).
Key Financial Metrics
| Total Revenue | $1.6M |
|---|---|
| Net Profit | $-5.8M |
| Gross Margin | N/A |
| Operating Margin | -380.2% |
| Report Period | Q2 FY2024 |
Pulmatrix, Inc. Annual Revenue by Year
Pulmatrix, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $7.3M).
Pulmatrix, Inc. Quarterly Revenue & Net Profit History
Pulmatrix, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2024 | $1.6M | -15.8% | $-5.8M | -374.4% |
| Q1 FY2024 | $5.9M | +292.6% | $825.0K | 14.0% |
| Q4 FY2023 | $2.2M | +28.9% | $-2.1M | -94.6% |
| Q3 FY2023 | $1.8M | -6.4% | $-3.8M | -215.3% |
| Q2 FY2023 | $1.8M | +38.5% | $-3.8M | -206.9% |
| Q1 FY2023 | $1.5M | +29.2% | $-4.4M | -296.7% |
| Q4 FY2022 | $1.7M | +274.6% | $-4.2M | -246.8% |
| Q3 FY2022 | $1.9M | +75.1% | $-5.1M | -269.9% |
Income Statement
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $1.7M | $1.5M | $1.8M | $1.8M | $2.2M | $5.9M | $1.6M |
| YoY Growth | 75.1% | 274.6% | 29.2% | 38.5% | -6.4% | 28.9% | 292.6% | -15.8% |
Balance Sheet
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $46.5M | $41.0M | $36.1M | $31.4M | $36.8M | $34.0M | $30.4M | $15.8M |
| Liabilities | $11.4M | $9.8M | $9.0M | $7.9M | $16.9M | $16.0M | $11.4M | $2.5M |
| Equity | $35.0M | $31.1M | $27.0M | $23.4M | $19.9M | $18.0M | $19.0M | $13.3M |
Cash Flow
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.6M | $-5.0M | $-4.9M | $-4.9M | $-4.1M | $-2.0M | $-2.7M | $-3.7M |